In part 3 of an interview with The American Journal of Managed Care®, Kiran Bhavaraju-Sanka, MD, and Beth Stein, MD, focus on how to optimize patient treatment selection for myasthenia gravis (MG). They discuss important considerations in the move toward a precision medicine approach in the space that include MG immunopathologic basis, defining disease subgroup, and patient comorbidities. TranscriptWill it be possible one day to predict patient response to enable a more personalized and effective MG treatment selection process? Beth Stein, MD: I think as we understand the immunopathologic basis of MG, we're able to establish and understand patient characteristics. You can personalize and tailor their care based on understanding their subgroup and using precision medicine to lead to more effective treatment.